Evaluating comfort and handling of new patient extension line and bag connector for Peritoneal Dialysis (PD). A short-term, open controlled study.

Submission date 11/01/2007	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 25/01/2007	Overall study status Completed	 Statistical analysis plan Results
Last Edited 25/01/2007	Condition category Urological and Genital Diseases	 Individual participant data Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Mrs Christina Schönborg

Contact details

Gambro Clinical Affairs Krokslätts Fabriker 32 Mölndal Sweden SE-431 37

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

1443

Study information

Scientific Title

Study objectives Evaluate patient satisfaction in a first filed utilisation before final desicion on product design.

Ethics approval required Old ethics approval format

Ethics approval(s) Ethics Committee at San Marino University Hospital in Genova , approved on 19/07/2006, ref: 0037753/06

Study design Open, controlled, single center, comparative prospective pilot study

Primary study design Interventional

Secondary study design Non randomised controlled trial

Study setting(s) Hospital

Study type(s) Quality of life

Participant information sheet

Health condition(s) or problem(s) studied

ESRD - End Stage Renal Disease

Interventions

Tested products: twist extension line combined with twist female connector on Gambrosol trio.

Reference products: current patient line (PDL 1201-8) and current Gambro CAPD system. All patients will be treated in a CAPD program exchangning Gambrosol trio GEM 20U03 Ca 2,5 with twist for 3 to 5 exchanges/day following their physician's prescription on glucose concentration to be used. Evaluation on patient satisfaction will be done with a questionnaire at three times: before switch to twist, after two weeks on twist and at four weeks on tested products (end of study).

Intervention Type Other

Phase Not Specified

Primary outcome measure Patient satisfaction on handling by comparing current system with new system, twist.

Secondary outcome measures Collect safety data on new patient line.

Overall study start date 22/01/2007

Completion date 10/03/2007

Eligibility

Key inclusion criteria

 Patients suffering from chronic renal failure
 Age 18 years or older
 Treated in a Continuous Ambulatory Peritoneal Dialysis (CAPD) program with Gambrosol trio (GEM 20U03 Ca 2,5)
 Treated on CAPD for at least 24 months
 Signed written informed consent to participate in the study

Participant type(s) Patient

Age group Adult

Lower age limit

18 Years

Sex Not Specified

Target number of participants 5

Key exclusion criteria

1. Pregnancy

2. HIV

3. Hepatitis

4. Participation in other studies during the study period if considered to cause interference with either of the studies

5. Treated in a haemodialysis program, patients with diagnosed abdominal pain not related with PD solution

6. Patients on night Automated Peritoneal Dialysis (APD)

7. Peritonitis within one month prior to the study

8. Presence of exit-site/tunnel infection or ongoing peritonitis 9. Impaired and /or disabled patients

Date of first enrolment 22/01/2007

Date of final enrolment 10/03/2007

Locations

Countries of recruitment Italy

Sweden

Study participating centre Gambro Mölndal Sweden SE-431 37

Sponsor information

Organisation

Gambro (Sweden)

Sponsor details

Clinical Affairs Emdalavägen 5 P.O. Box 10101 Lund Sweden SE 220 10

Sponsor type

Industry

Website http://www.gambro.com/start.aspx?id=752

ROR

https://ror.org/05mw5ed57

Funder(s)

Funder type Industry

Funder Name Gambro (Sweden)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not provided at time of registration